Citius Pharmaceuticals Inc (NASDAQ:CTXR) insider Leonard L. Mazur acquired 421,400 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were bought at an average cost of $4.13 per share, with a total value of $1,740,382.00. Following the acquisition, the insider now directly owns 1,779,663 shares in the company, valued at $7,350,008.19. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Citius Pharmaceuticals Inc (NASDAQ CTXR) traded down 3.02% on Thursday, hitting $2.89. 13,263 shares of the company’s stock traded hands. The stock has a 50-day moving average of $6.63 and a 200-day moving average of $6.50. Citius Pharmaceuticals Inc has a one year low of $2.75 and a one year high of $25.65. The stock’s market cap is $14.55 million.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/citius-pharmaceuticals-inc-ctxr-insider-leonard-l-mazur-purchases-421400-shares/1470880.html.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream.

Receive News & Ratings for Citius Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.